Mandate

Vinge has acted for NatWest Markets N.V. in connection with an increase of existing securitisation

October 19, 2022

Vinge has acted for NatWest Markets N.V. as senior noteholder in connection with an amendment and restatement of the existing note facilities agreement with DBT Capital AB as originator and its subsidiary as issuer (jointly “DBT”). The amendment and restatement included, among other things, an increase of the aggregate amount of the facilities to up to SEK 3,100,000,000 and an introduction of an entity controlled by global investment firm Värde Partners as a mezzanine noteholder. The financing is part of a securitisation of secured loans to small and medium sized enterprises (SMEs) originated by DBT.

DBT is a Swedish private lender registered with the Swedish Financial Supervisory Authority and who offers corporate loans and financing to SMEs in Sweden.

The transaction is executed and reported under the EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and is subject to the reporting requirements thereunder.

Vinge’s team consisted primarily of responsible partner Albert Wållgren together with associates Seyran Sahin, Axel Jansson, Ulf Pyk and Calle Tengwall Pagels.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025